This bill funds the Departments of Labor, Health and Human Services (HHS), and Education for FY2026 and specifies detailed dollar allocations across hundreds of programs, from WIOA workforce grants and Job Corps to NIH, CDC, BARDA/ASPR, Head Start, Pell, and K–12 formula grants. It combines classic annual appropriations language (account-by-account dollar amounts, availability periods, and rescissions) with an unusually large number of substantive riders that restrict agency rulemaking, impose programmatic conditions, and direct procurement and grant priorities.
For practitioners the package matters for two reasons. First, it establishes the FY2026 fiscal baseline — including major line items such as workforce and apprenticeship funding, NIH and ARPA‑H/NIH Innovation dollars, ASPR/BARDA countermeasure funding, and K–12 and higher‑education buckets (including a specified Pell maximum).
Second, it imposes dozens of policy limits that will reshape implementation: it precludes enforcement of several Department of Labor rules, constrains Title X and reproductive‑health funding, restricts certain HHS regulations and executive‑order implementation, conditions partnerships and procurements, and rescinds significant prior balances. Compliance officers, grant managers, health system leaders, and higher‑education officials will need to track both the funding streams and the attached statutory prohibitions.
At a Glance
What It Does
Appropriates FY2026 funds for Labor, HHS and Education accounts and specifies availability periods and rescissions; earmarks and program set‑asides alongside authorities to transfer small shares between accounts. The bill also inserts dozens of policy riders that prohibit agencies from implementing or enforcing named rules and policies, limit the use of funds for reproductive services and certain research, and direct pandemic preparedness procurements.
Who It Affects
Federal program offices (DOL, HHS/CDC/NIH/SAMHSA/ASPR, ED), state workforce and unemployment agencies, hospitals and public‑health providers, Title X grantees and family‑planning clinics, higher‑education institutions and research partners, employers using temporary foreign labor programs (H‑2B/H‑2A), and manufacturers and contractors eligible for BARDA/ASPR awards.
Why It Matters
Beyond dollar totals, the bill ties funding to policy outcomes: it funds large pandemic‑preparedness buys while restricting certain public‑health and regulatory authorities (and some research and provider activities). The net effect will be both programmatic gains (new procurement and grant dollars) and operational limits that agencies must navigate, with significant compliance, legal, and operational implications for recipients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is an annual Labor–HHS–Education appropriations measure that combines straightforward budget allocations with detailed policy direction. On the Labor side, it funds Employment and Training Administration programs (WIOA, apprenticeships, Job Corps), state unemployment and employment service operations, veterans’ employment programs, OSHA and MSHA enforcement and training, and several program integrity and IT modernization set‑asides.
A recurring theme in the Labor title is the combination of formula and competitive grant funding with provisions that adjust eligibility, reporting, and allowable transfers.
HHS receives large appropriations across HRSA, CDC, NIH, SAMHSA, ASPR/BARDA, and public‑health preparedness. Notable programmatic commitments include multi‑hundred‑million and multi‑billion dollar accounts for medical countermeasures and pandemic preparedness (large BARDA/ASPR appropriations with line‑item instructions), a near‑billion dollar ARPA‑type account for advanced health projects, and continued NIH research funding with specified account totals.
The bill also contains repeated prohibitions on use of funds for certain activities—most prominently, restrictions on Title X implementation, prohibitions on using funds for abortion services and for entities that perform or fund abortions, and specific bans on implementing or enforcing a long list of rulemakings and executive actions the sponsors identify as disfavored.The Education title funds K–12 formula programs (Title I, Impact Aid, school improvement grants), higher education (including supplemental grants to HBCUs and specific carve‑outs for institutions and programs), Perkins Career and Technical Education, Pell and student financial aid (it fixes the Pell maximum for the award year), and the Institute of Education Sciences. It also includes programmatic riders limiting or conditioning campus policies (e.g., restrictions tied to campus religious student organizations) and forbids use of funds for specific federal higher‑education rulemakings and student‑loan policy changes.Across the bill there are transaction‑level mechanics that matter to implementers: rescissions of prior unobligated balances (including a large rescission from the Child Enrollment Contingency Fund), multiple transfer authorities subject to 15‑day notifications to appropriations committees, strict reprogramming and reporting requirements, and carve‑outs for state and tribal set‑asides.
The combination of explicit dollar directions with statutory riders means that recipients must track both budget language and the many programmatic conditions that determine allowable activities.
The Five Things You Need to Know
The bill provides $3.265 billion to ASPR for medical countermeasures and pandemic preparedness, with sub‑allocations (for FY2026) including $1.1 billion for advanced R&D, $850 million for procurement of security countermeasures, $1.0 billion for Strategic National Stockpile activities, and $315 million targeted to influenza pandemic preparedness.
It authorizes a 120‑day ‘‘crossing’’ window for H‑2B workers in the seafood industry (employers may bring nonimmigrants in during a 120‑day period); but after day 90 employers must re‑advertise locally and offer work to equally or better qualified U.S. workers before bringing workers across.
The bill bars use of funds to implement or enforce an explicit list of rules and regulatory changes, including DOL’s 2023 H‑2A AEWR/adverse effect wage rate methodology, H‑2A joint employer changes, and the final Department of Labor ‘‘employee or independent contractor’’ rule (89 Fed. Reg. 1638), among others.
It rescinds $12.835 billion from the Social Security Child Enrollment Contingency Fund balances and rescinds specified unobligated ARP balances (totaling $183 million) — large one‑time reductions that affect available prior‑year resources.
The Pell maximum for award year 2026–2027 is set in the bill at $6,335, and the bill provides $23.25 billion for student financial assistance with Student Aid Administration and IT support funded separately.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Workforce funding, visa flexibilities, and rule prohibitions
This section allocates core WIOA, apprenticeship, Job Corps, and unemployment administration funding while attaching operational limits. Mechanically it specifies multi‑year availability dates and rescinds a prior onetime WIOA balance; it also creates transfer authority for program integrity and evaluation. Practically, compliance officers must watch the bill’s explicit prohibitions on funding to implement several DOL rulemakings and the new H‑2B/H‑2A directives (for example, the seafood industry crossing window and prevailing wage acceptance rules). These riders change how employers, State workforce agencies, and DOL program offices will operationalize recruitment, prevailing wage determinations, and audits.
Large pandemic preparedness buys and constrained regulatory latitude
HHS receives major increases for countermeasure development and procurement through BARDA/ASPR, plus multi‑year NIH investments (including $945M for ARPA‑type advanced health projects). The bill directs explicit line‑item uses: advanced R&D, procurement for the stockpile, and influenza pandemic production capacity, and it authorizes deposit of user fees to support OPTN and other programs. Counterbalancing funding, the statute contains numerous policy riders that prohibit use of funds for certain rulemakings, restrict Title X and reproductive‑health funding, ban use of funds for particular CDC/NIH regulations and for DEI/CRT program elements, and restrict partnerships or purchases from specified foreign entities. Implementation will require cross‑office legal and contracting reviews to reconcile procurement priorities with expressed prohibitions.
Formula grants, Pell, HBCU and programmatic riders
This title sets K–12 formula totals (Title I, Impact Aid, School Improvement, ESSA subparts) and higher‑education accounts (including Perkins, HEA Titles II–VIII, HBCU capital financing, and explicit language for Pell and the Pell maximum). It includes programmatic riders prohibiting use of funds to implement several recent Department rules (student debt relief, gainful employment, employer/contractor classification rules, etc.), and contains carve‑outs limiting Title IX enforcement actions tied to certain gender identity/sexual orientation interpretations. Grant managers and postsecondary compliance offices must update policy and award documents to reflect the substituted statutory authorities and prohibitions.
Reproductive‑health, research, and rule bans
The bill contains multiple general provisions limiting funding for abortions, forbidding funding for Title X recipients that perform or refer for abortion, and restricting federally funded research in defined areas (e.g., human embryos from induced abortions and certain types of research collaborations). It also forbids implementation or enforcement of specifically named regulations and several Executive Orders related to climate, DEI, and COVID mandates. Those riders are statutory controls—administrative offices must interpret them in grant conditions, contracting language, and rulemaking plans.
Reprogramming limits, rescissions, and reporting
The bill tightens reprogramming authorities, requires 15‑day notices for transfers, and demands frequent reporting on grants, non‑competitive awards, unobligated balances, and prior‑year funds. It rescinds significant balances (notably $12.835B from the Child Enrollment Contingency Fund and selected ARP unobligated balances). Agencies must adjust internal budget execution systems to accommodate the rescissions and the tighter consultation windows before any reallocation.
This bill is one of many.
Codify tracks hundreds of bills on Government across all five countries.
Explore Government in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medical countermeasure manufacturers and domestic producers: the bill directs multi‑hundred‑million and multi‑billion dollar investments through ASPR/BARDA for advanced R&D, procurement, and influenza production capacity that create opportunities for awards and manufacturing scale‑up.
- NIH and advanced biomedical research programs: the measure funds ARPA‑style projects (ARPA‑H/NIH Innovation accounts) and preserves large institute funding lines, sustaining grants, contracts, and clinical research pipelines.
- State workforce agencies and community colleges: sustained and explicit WIOA, apprenticeship, and Job Corps funding (including earmarks for community‑college–led training) supports training pipelines and reemployment services.
- K–12 districts and high‑need schools: Title I, school improvement, Impact Aid, and school safety funds provide formula and competitive dollars for districts that serve high‑poverty and federally impacted students.
- Employers in the seafood/H‑2B sector: the bill’s 120‑day crossing flexibility provides a defined operational window to deploy H‑2B workers, reducing immediate logistical constraints for seasonal seafood operations.
Who Bears the Cost
- Title X and family‑planning clinics that provide abortion referrals or services: the bill bars certain Title X funding pathways and imposes certification requirements that can reduce federal support or contract eligibility.
- Federal agency rulemakers and program offices: the statute forbids enforcement or implementation of several named rules and EOs, constraining agency regulatory options and creating potential legal conflicts to manage.
- Universities and research institutions with PRC ties: the bill restricts collaborations and procurements with certain foreign entities and bars funding where partnerships or purchases run afoul of named prohibitions, forcing compliance reviews and potential project terminations.
- Recipients of prior‑year contingency funds and programs reliant on rescinded balances: the large rescission of the Child Enrollment Contingency Fund and selected unobligated ARP balances reduces available carryover for contingency response and state‑program top‑ups.
- Grantmakers and contracting offices: heightened preaward reporting, 15‑day notification windows, and tighter reprogramming rules increase administrative overhead and slow internal budget flexibility.
Key Issues
The Core Tension
The central dilemma is that Congress funds large and urgent public‑health and workforce priorities (more dollars for countermeasures, NIH research, apprenticeships, Pell, and K–12) while at the same time using appropriations riders to strip agencies of regulatory tools and to prohibit entire categories of activities (certain public‑health rules, reproductive services, research collaborations, and diversity/equity programs). That solves one problem—money for programs—while creating new operational and legal constraints that could blunt the effectiveness of the very programs the bill funds.
The bill simultaneously increases funding for preparedness, biomedical research, workforce development, and education while restricting large swaths of agency regulatory and programmatic authority. That design creates genuine implementation friction: agencies must accept statutorily directed procurement priorities (for example, BARDA buying countermeasures) while complying with express bans on implementing particular rulemakings or policy positions.
Practically this raises questions about procurement sourcing, allowed collaborations, and how to reconcile line‑item buys with prohibited partnerships or purchases. For recipients, granular prohibitions (for example, the Title X and abortion‑related rules, bans on certain research activities, and limits on partnerships with specified foreign entities) will require contract clauses, certifications, and enhanced legal review prior to award.
From an operational perspective, the bill also tightens budget discipline (reprogramming thresholds, 15‑day notice rules) and imposes multiple reporting obligations. Those mechanics improve congressional oversight but can delay reallocation in real time.
Finally, several provisions—especially the long lists of rules that agencies are forbidden to enforce—are phrased as anti‑funding commands (‘‘none of the funds may be used to implement or enforce…’’) and are likely to invite legal challenge or administrative confusion about agency authority versus statutory riders. Agencies will need to parse which prohibitions are unambiguous and which leave room for interpretation, while recipients will need rapid compliance tools to avoid deobligation or disallowed cost findings.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.